Pivotal Novartis Phase III psoriasis results at EADV

Novartis has announced results from the head-to-head Phase III FIXTURE study showing secukinumab (AIN457), an interleukin-17A (IL-17A) inhibitor, was significantly superior to Enbrel®* (etanercept) in moderate-to-severe plaque psoriasis

Source: Pharmacy Europe - October 3, 2013 Category: Drugs & Pharmacology Authors: ebercott Tags: *** Editor's Pick Dermatology Latest News Source Type: news